INTEGRILIN^® (eptifibatide) Injection, a GP IIb-IIIa inhibitor, is indicated for the treatment of patients with acute coronary syndrome (ACS), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI), including those undergoing intracoronary stenting. INTEGRILIN prevents the aggregation of blood platelets that can obstruct the flow of blood through the coronary arteries. INTEGRILIN can be administered upon diagnosis, including in the emergency room setting, regardless of whether the patient ultimately undergoes PCI or drug therapy alone. Treatment with INTEGRILIN has been shown to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS and the composite of death, MI, or need for urgent revascularization in patients undergoing PCI.

As of September 1, 2005, Schering-Plough Corporation and Millennium restructured their collaboration to optimize the growth potential of INTEGRILIN. Under the new relationship, Schering-Plough has exclusive development and commercialization rights to INTEGRILIN in the U.S. and Millennium receives a royalty for sales of the product. Schering-Plough and Millennium had been co- promoting INTEGRILIN in the United States and sharing profits since 2002. European marketing rights to INTEGRILIN are licensed to GlaxoSmithKline plc.

For full Prescribing Information, click here. (PDF)(742k)